EGFR and non-small cell lung carcinoma: Although EGFR-tyrosine kinase inhibitors (EGFR-TKI, such as gefitinib or erlotinib) have resulted in significant clinical benefit in patients with EGFR-mutant NSCLC [2, 3], acquired resistance inevitably develops [4].